TELA Bio, Inc.

NasdaqGM:TELA Stock Report

Market Cap: US$50.3m

TELA Bio Management

Management criteria checks 3/4

TELA Bio's CEO is Antony Koblish, appointed in Apr 2012, has a tenure of 13.67 years. total yearly compensation is $2.11M, comprised of 29.3% salary and 70.7% bonuses, including company stock and options. directly owns 0.78% of the company’s shares, worth $390.75K. The average tenure of the management team and the board of directors is 4.1 years and 5.9 years respectively.

Key information

Antony Koblish

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage29.34%
CEO tenure13.7yrs
CEO ownership0.8%
Management average tenure4.1yrs
Board average tenure5.9yrs

Recent management updates

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

Recent updates

Positive Sentiment Still Eludes TELA Bio, Inc. (NASDAQ:TELA) Following 26% Share Price Slump

Nov 14
Positive Sentiment Still Eludes TELA Bio, Inc. (NASDAQ:TELA) Following 26% Share Price Slump

Further Upside For TELA Bio, Inc. (NASDAQ:TELA) Shares Could Introduce Price Risks After 32% Bounce

Jul 18
Further Upside For TELA Bio, Inc. (NASDAQ:TELA) Shares Could Introduce Price Risks After 32% Bounce

Investors Still Aren't Entirely Convinced By TELA Bio, Inc.'s (NASDAQ:TELA) Revenues Despite 39% Price Jump

May 21
Investors Still Aren't Entirely Convinced By TELA Bio, Inc.'s (NASDAQ:TELA) Revenues Despite 39% Price Jump

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50%

Mar 31
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50%

Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Nov 09
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Aug 19
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Jul 03
Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

May 23
TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 24
Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

Mar 08
Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Oct 07
TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

Jul 31
Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Oct 02

Tela Bio prices $32M common stock offering

Aug 16

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

May 12
Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio - Follow Up With Management

Jan 14

Our First Look At TELA Bio

Nov 04

TELA Bio Plugging Away

Oct 25

CEO Compensation Analysis

How has Antony Koblish's remuneration changed compared to TELA Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$39m

Jun 30 2025n/an/a

-US$41m

Mar 31 2025n/an/a

-US$43m

Dec 31 2024US$2mUS$618k

-US$38m

Sep 30 2024n/an/a

-US$42m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$2mUS$595k

-US$47m

Sep 30 2023n/an/a

-US$44m

Jun 30 2023n/an/a

-US$44m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$566k

-US$44m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022n/an/a

-US$40m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$2mUS$538k

-US$33m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$806kUS$479k

-US$29m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$29m

Dec 31 2019US$2mUS$403k

-US$30m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$30m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$569kUS$375k

-US$30m

Compensation vs Market: Antony's total compensation ($USD2.11M) is above average for companies of similar size in the US market ($USD573.27K).

Compensation vs Earnings: Antony's compensation has been consistent with company performance over the past year.

CEO

Antony Koblish (59 yo)

13.7yrs
Tenure
US$2,105,341
Compensation

Mr. Antony Koblish is Chairman of The Board of Onkos Surgical, Inc. Mr. Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the Director and Chief Executive Officer of TELA Bio, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Antony Koblish
Co-founder13.7yrsUS$2.11m0.78%
$ 390.8k
Jeffrey Blizard
President of TELA Bio & Directorless than a yearUS$88.40k0%
$ 0
Roberto Cuca
CFO & COO4.3yrsUS$1.08m0.26%
$ 131.6k
Paul Talmo
Chief Technology Officerno dataUS$816.61k0.14%
$ 70.6k
Megan Smeykal
VP, Corporate Controller4.6yrsno data0.033%
$ 16.6k
D. Ocasio
General Counsel & Corporate Secretary3.7yrsno datano data
Jim Hagen
Senior VP of Strategic Commercial Operations & Marketingno datano datano data
Jennifer Armstrong
Senior Vice President of Human Resources3.9yrsno datano data
Gregory Firestone
Chief Commercial Officerno datano data0.24%
$ 122.8k
Michael Leonard
Senior Vice President of Technical Operations3.9yrsno datano data
Peter Murphy
Chief Commercial Officer5.9yrsUS$936.76k0.031%
$ 15.6k
Louisa Smith
Investor Relations Contact Officerno datano datano data
4.1yrs
Average Tenure
55.5yo
Average Age

Experienced Management: TELA's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Antony Koblish
Co-founder13.7yrsUS$2.11m0.78%
$ 390.8k
Jeffrey Blizard
President of TELA Bio & Director1.5yrsUS$88.40k0%
$ 0
Vincent Burgess
Independent Director13yrsUS$107.68k0.035%
$ 17.7k
Federica O'Brien
Independent Director6.1yrsUS$112.68k0.024%
$ 12.1k
Douglas Evans
Independent Chairman of the Board5.7yrsUS$148.70k0.024%
$ 12.1k
Kurt Azarbarzin
Independent Director7.1yrsUS$105.25k0.024%
$ 12.1k
William Plovanic
Directorless than a yearno datano data
Betty Rocchio
Directorless than a yearno datano data
5.9yrs
Average Tenure
60yo
Average Age

Experienced Board: TELA's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/15 21:56
End of Day Share Price 2025/12/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TELA Bio, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PlovanicCanaccord Genuity
Caitlin CroninCanaccord Genuity
David TurkalyCitizens JMP Securities, LLC